Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Cash (2016 - 2025)

Historic Change in Cash for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$16.8 million.

  • Spyre Therapeutics' Change in Cash fell 16418.53% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year increase of 6710.96%. This contributed to the annual value of -$99.8 million for FY2024, which is 16530.93% down from last year.
  • Latest data reveals that Spyre Therapeutics reported Change in Cash of -$16.8 million as of Q3 2025, which was down 16418.53% from $33.2 million recorded in Q2 2025.
  • Spyre Therapeutics' Change in Cash's 5-year high stood at $200.1 million during Q2 2023, with a 5-year trough of -$182.4 million in Q2 2024.
  • Moreover, its 5-year median value for Change in Cash was -$515000.0 (2022), whereas its average is -$1.4 million.
  • Per our database at Business Quant, Spyre Therapeutics' Change in Cash crashed by 1173794.21% in 2023 and then soared by 2811605.84% in 2024.
  • Spyre Therapeutics' Change in Cash (Quarter) stood at -$9.5 million in 2021, then soared by 56.92% to -$4.1 million in 2022, then surged by 2472.4% to $97.3 million in 2023, then plummeted by 81.66% to $17.8 million in 2024, then plummeted by 193.94% to -$16.8 million in 2025.
  • Its Change in Cash stands at -$16.8 million for Q3 2025, versus $33.2 million for Q2 2025 and -$40.9 million for Q1 2025.